Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Sedlacek, Petr  [Clear All Filters]
2014
Angelucci E, Matthes-Martin S, Baronciani D, Bernaudin F, Bonanomi S, Cappellini MDomenica, Dalle J-H, Di Bartolomeo P, de Heredia CDíaz, Dickerhoff R, et al. Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. Haematologica. 2014;99(5):811-820.
Tesfaye H, Branova R, Klapkova E, Prusa R, Janeckova D, Riha P, Sedlacek P, Keslova P, Malis J. The importance of Therapeutic Drug Monitoring (TDM) for parenteral busulfan dosing in conditioning regimen for Hematopoietic Stem Cell Transplantation (HSCT) in children. Ann Transplant. 2014;19:214-224.
2015
Wlodarski MW, Hirabayashi S, Pastor V, Stary J, Hasle H, Masetti R, Dworzak M, Schmugge M, van den Heuvel-Eibrink M, Ussowicz M, et al. Prevalence, clinical characteristics and prognosis of GATA2-related myelodysplastic syndromes (MDS) in children and adolescents. Blood. 2015.
2019
Ferrua F, Galimberti S, Courteille V, Slatter MAnne, Booth C, Moshous D, Neven B, Blanche S, Laberko A, Shcherbina A, et al. Hematopoietic stem cell transplantation for CD40 ligand deficiency: results from an EBMT/ESID-IEWP-SCETIDE-PIDTC Study. J Allergy Clin Immunol. 2019.
Balduzzi A, Dalle J-H, Wachowiak J, Yaniv I, Yeşilipek A, Sedlacek P, Bierings M, Ifversen M, Sufliarska S, Kalwak K, et al. TRANSPLANTATION IN CHILDREN AND ADOLESCENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA FROM A MATCHED DONOR VERSUS AN HLA-IDENTICAL SIBLING: IS THE OUTCOME COMPARABLE? RESULTS FROM THE INTERNATIONAL BFM ALL SCT 2007 STUDY. Biol Blood Marrow Transplant. 2019.
2020
Willasch AManfred, Peters C, Sedlacek P, Dalle J-H, Kitra-Roussou V, Yeşilipek A, Wachowiak J, Lankester A, Prete A, Hamidieh AAli, et al. Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?-A multicenter EBMT-PDWP study. Bone Marrow Transplant. 2020.
Kalwak K, Mielcarek M, Patrick K, Styczyński J, Bader P, Corbacioglu S, Burkhardt B, Sykora KWalter, Drabko K, Goździk J, et al. Treosulfan-fludarabine-thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies. Bone Marrow Transplant. 2020.
2022
Albert MH, Slatter MA, Gennery AR, Güngör T, Bakunina K, Markovitch B, Hazelaar S, Sirait T, Courteille V, Aiuti A, et al. Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT inborn errors working party analysis. Blood. 2022.
2023
Bader P, Poetschger U, Dalle J-H, Moser LM, Balduzzi ACristina, Ansari M, Buechner J, Güngör T, Ifversen M, Kriván G, et al. Low rate of nonrelapse mortality in under 4-year-olds with ALL given chemo-conditioning for HSCT: Phase III FORUM study. Blood Adv. 2023.
Sembill S, Ampatzidou M, Chaudhury S, Dworzak M, Kalwak K, Karow A, Kiani A, Krumbholz M, Luesink M, Naumann-Bartsch N, et al. Management of children and adolescents with chronic myeloid leukemia in blast phase: International pediatric CML expert panel recommendations. Leukemia. 2023.
Sykora K-W, Beier R, Schulz A, Cesaro S, Greil J, Goździk J, Sedlacek P, Bader P, Schulte J, Zecca M, et al. Treosulfan vs busulfan conditioning for allogeneic bmt in children with nonmalignant disease: a randomized phase 2 trial. Bone Marrow Transplant. 2023.
2024
Sharma A, Galimard J-E, Pryce A, Bhoopalan SVelan, Dalissier A, Dalle J-H, Locatelli F, Jubert C, Mirci-Danicar O, Kitra-Roussou V, et al. Cytogenetic abnormalities predict survival after allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia: a PDWP/EBMT study. Bone Marrow Transplant. 2024.